These findings highlight the metabolic hazards associated with SPARCL1, suggesting that blocking its action, such as through the use of neutralizing antibody, could serve as a potential therapy for treating MASLD/MASH. Here, SPARCL1 is linked to metabolic dysfunction-associated steatohepatitis.